BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hassn Mesrati M, Behrooz AB, Y Abuhamad A, Syahir A. Understanding Glioblastoma Biomarkers: Knocking a Mountain with a Hammer. Cells 2020;9:E1236. [PMID: 32429463 DOI: 10.3390/cells9051236] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Singh N, Miner A, Hennis L, Mittal S. Mechanisms of temozolomide resistance in glioblastoma - a comprehensive review. Cancer Drug Resist 2021;4:17-43. [PMID: 34337348 DOI: 10.20517/cdr.2020.79] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Polano M, Fabbiani E, Adreuzzi E, Cintio FD, Bedon L, Gentilini D, Mongiat M, Ius T, Arcicasa M, Skrap M, Dal Bo M, Toffoli G. A New Epigenetic Model to Stratify Glioma Patients According to Their Immunosuppressive State. Cells 2021;10:576. [PMID: 33807997 DOI: 10.3390/cells10030576] [Reference Citation Analysis]
3 Lu W, Chen H, Liang B, Ou C, Zhang M, Yue Q, Xie J. Integrative Analyses and Verification of the Expression and Prognostic Significance for RCN1 in Glioblastoma Multiforme. Front Mol Biosci 2021;8:736947. [PMID: 34722631 DOI: 10.3389/fmolb.2021.736947] [Reference Citation Analysis]
4 Cardoso AM, Morais CM, Pena F, Marante T, Cunha PP, Jurado AS, Pedroso de Lima MC. Differentiation of glioblastoma stem cells promoted by miR-128 or miR-302a overexpression enhances senescence-associated cytotoxicity of axitinib. Hum Mol Genet 2021;30:160-71. [PMID: 33438013 DOI: 10.1093/hmg/ddab011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Li Q, Aishwarya S, Li J, Pan D, Shi J. Gene Expression Profiling of Glioblastoma to Recognize Potential Biomarker Candidates. Front Genet 2022;13:832742. [DOI: 10.3389/fgene.2022.832742] [Reference Citation Analysis]
6 Vasileva N, Ageenko A, Dmitrieva M, Nushtaeva A, Mishinov S, Kochneva G, Richter V, Kuligina E. Double Recombinant Vaccinia Virus: A Candidate Drug against Human Glioblastoma. Life (Basel) 2021;11:1084. [PMID: 34685455 DOI: 10.3390/life11101084] [Reference Citation Analysis]
7 Maggio I, Franceschi E, Gatto L, Tosoni A, Di Nunno V, Tonon C, Brandes AA. Radiomics, mirnomics, and radiomirRNomics in glioblastoma: defining tumor biology from shadow to light. Expert Rev Anticancer Ther 2021;21:1265-72. [PMID: 34433354 DOI: 10.1080/14737140.2021.1971518] [Reference Citation Analysis]
8 Behrooz AB, Syahir A. Could We Address the Interplay Between CD133, Wnt/β-Catenin, and TERT Signaling Pathways as a Potential Target for Glioblastoma Therapy? Front Oncol 2021;11:642719. [PMID: 33869033 DOI: 10.3389/fonc.2021.642719] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Vasileva NS, Ageenko AB, Richter VA, Kuligina EV. The Signaling Pathways Controlling the Efficacy of Glioblastoma Therapy. Acta Naturae 2022;14:62-70. [DOI: 10.32607/actanaturae.11623] [Reference Citation Analysis]
10 Mahinfar P, Mansoori B, Rostamzadeh D, Baradaran B, Cho WC, Mansoori B. The Role of microRNAs in Multidrug Resistance of Glioblastoma. Cancers 2022;14:3217. [DOI: 10.3390/cancers14133217] [Reference Citation Analysis]
11 Safaee MM, Wang EJ, Jain S, Chen JS, Gill S, Zheng AC, Garcia JH, Beniwal AS, Tran Y, Nguyen AT, Trieu M, Leung K, Wells J, Maclean JM, Wycoff K, Aghi MK. CD97 is associated with mitogenic pathway activation, metabolic reprogramming, and immune microenvironment changes in glioblastoma. Sci Rep 2022;12:1464. [PMID: 35087132 DOI: 10.1038/s41598-022-05259-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Habič A, Novak M, Majc B, Lah Turnšek T, Breznik B. Proteases Regulate Cancer Stem Cell Properties and Remodel Their Microenvironment. J Histochem Cytochem 2021;:221554211035192. [PMID: 34310223 DOI: 10.1369/00221554211035192] [Reference Citation Analysis]
13 Li R, Jiang Q, Tang C, Chen L, Kong D, Zou C, Lin Y, Luo J, Zou D. Identification of Candidate Genes Associated With Prognosis in Glioblastoma. Front Mol Neurosci 2022;15:913328. [DOI: 10.3389/fnmol.2022.913328] [Reference Citation Analysis]
14 Hassn Mesrati M, Syafruddin SE, Mohtar MA, Syahir A. CD44: A Multifunctional Mediator of Cancer Progression. Biomolecules 2021;11:1850. [PMID: 34944493 DOI: 10.3390/biom11121850] [Reference Citation Analysis]
15 Wu W, Klockow JL, Zhang M, Lafortune F, Chang E, Jin L, Wu Y, Daldrup-Link HE. Glioblastoma multiforme (GBM): An overview of current therapies and mechanisms of resistance. Pharmacol Res 2021;171:105780. [PMID: 34302977 DOI: 10.1016/j.phrs.2021.105780] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Warrier NM, Krishnan RK, Prabhu V, Hariharapura RC, Agarwal P, Kumar P. Survivin Inhibition by Piperine Sensitizes Glioblastoma Cancer Stem Cells and Leads to Better Drug Response. Int J Mol Sci 2022;23:7604. [PMID: 35886952 DOI: 10.3390/ijms23147604] [Reference Citation Analysis]
17 Wei L, Zou C, Chen L, Lin Y, Liang L, Hu B, Mao Y, Zou D. Molecular Insights and Prognosis Associated With RBM8A in Glioblastoma. Front Mol Biosci 2022;9:876603. [DOI: 10.3389/fmolb.2022.876603] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Tsai YT, Wu CC, Ko CY, Hsu TI, Chang WC, Lo WL, Chuang JY. Correlation between the expression of cancer stem cell marker BMI1 and glioma prognosis. Biochem Biophys Res Commun 2021;550:113-9. [PMID: 33691197 DOI: 10.1016/j.bbrc.2021.02.140] [Cited by in F6Publishing: 1] [Reference Citation Analysis]